[Lepirudin for therapeutic use in heparin-induced thrombocytopenia].
Heparin-induced thrombocytopenia (HIT) type II is an antibody mediated severe adverse event to heparin with a paradoxical decrease of platelet count and an increased risk for thromboembolic complications. The antibodies are directed against a neoepitop of platelet factor 4 after its binding to heparin. The incidence of HIT type II is lower with low-molecular-weight heparin compared to unfractionated heparin and lower in not operated patients compared to those after major surgery. In patients with HIT type II alternative anticoagulation has to be performed immediately due to the high thrombogenicity of the antibodies. The recombinant hirudin lepirudin (Refludan) is the anticoagulant drug of choice. A long-term anticoagulation has to be performed depending on the concomitant risk factors, intravenous administration followed by subcutaneous lepirudin overlapping with vitamin K antagonists.
Harenberg
J
J
IV. Medizinische Klinik, Universitätsklinikum Mannheim, Theodor-Kutzer-Ufer, 68167 Mannheim. J-Harenberg@t-online.de
Jörg
I
I
Koch
S
S
Fenyvesi
T
T
D000925:Anticoagulants / Q000009:adverse effects; D003937:Diagnosis, Differential; D006493:Heparin / Q000009:adverse effects*; D006629:Hirudins / Q000031:analogs & derivatives; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000145:classification / Q000188:drug therapy*
D000925:Anticoagulants; D006629:Hirudins; D011994:Recombinant Proteins; D006493:Heparin; C083544:lepirudin